Wirkung von Handmassagestimulation auf Schmerz und Menstruationsbeschwerden bei primärer Dysmenorrhoe
Wirkung einer Handmassage-Stimulation auf Schmerzen und Menstruationsbeschwerden bei primärer Dysmenorrhoe
Purpose of this study: The purpose of this study is to determine the effect of hand massage stimulation techniques on pain, daily menstrual symptoms and nausea and vomiting in primary dysmenorrhea.
H1a: Hand massage stimulation techniques reduce pain in primary dysmenorrhea. H1b: Hand massage stimulation techniques reduce daily menstrual symptoms in primary dysmenorrhea.
The data were collected from students suffering from primary dysmenorrhea pain studying at İnönü University Faculty of Health Sciences. Seed therapy (su-jok) will be applied by researcher Melike TAN ÇELİK who has a basic level su-jok therapy certificate.
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
The aim of this study is to determine the effect of hand massage stimulation techniques on pain, daily menstrual symptoms and nausea and vomiting in primary dysmenorrhea.
Data will be collected from students experiencing Primary Dysmenorrhea at İnönü University Faculty of Health Sciences. Participants who meet the inclusion criteria and agree to participate will be informed about the study, and participants who fill out the "Minimum Informed Consent Form" will be included in the study. Data collection forms will be applied by the researcher, paying attention to student privacy, and the pre-test data collection phase will be completed. After the pre-test data collection phase is completed, hand stimulation techniques (su-jok seed therapy) will be applied by the researcher to the students experiencing primary dysmenorrhea in the experimental group. Students experiencing primary dysmenorrhea will be given detailed information about the application in the laboratory at the faculty, and pain points will be determined according to the reflections of the organs on the hand. Black pepper seeds, one of the seeds used in the treatment of primary dysmenorrhea, will be placed on the detected points and removed after 5-6 hours. This application will be done a total of 3 times in each cycle, on the 1st, 2nd and 3rd day of the menstrual cycle. A total of 2 cycles of application will be made, the first menstrual cycle being the 1st cycle, and the final test data will be collected 5-6 hours after each application. This intervention will be carried out by Melike Tan, and the researcher has a basic level Su Jok therapy certificate. No intervention will be applied to the students experiencing primary dysmenorrhea in the control group, but the Personal Information Form, Visual Analog Scale (VAS), and Daily Menstrual Symptom Assessment Scale (GMDSS) will be administered simultaneously to the experimental group.
Studientyp
Einschreibung (Tatsächlich)
Phase
- Unzutreffend
Kontakte und Standorte
Studienorte
-
-
-
Malatya, Türkei (türkiye)
- İnönü University Faculty of Health Sciences
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Participant who is 18 years or older
- Participant diagnosed with primary dysmenorrhea by a gynecologist
- Participant who has had regular menstruation in the last 6 months
- Participant whose menstrual pain continues for 8-72 hours
Exclusion Criteria:
- Participant who is pregnant
- Participant who has given birth before or has a history of pregnancy
- Participant using intrauterine or oral contraceptives
- Participant who is taking any anti-inflammatory, analgesic and psychotherapeutic medication
- Participant with any history of pelvic pathology or pelvic surgery
- Participant with any neurological or systemic disease
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Unterstützende Pflege
- Zuteilung: Zufällig
- Interventionsmodell: Crossover-Aufgabe
- Maskierung: Single
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: seed therapy ( su-jok)
Group that received seed therapy ( su- jok ) |
In hand massage, tiny swellings called "ball conformity" occur on the reflection points of the organs where the complaint occurs on the hands and feet. It is argued that the sensitivity of the relevant point to pressure has a direct correlation with the level of pain in the body part. A rod called a "diagnostic probe" or "diagnostic rod" made of metal, plastic or wood, approximately ten centimeters long, is used to detect the painful point on the hand and foot. After the correct point is detected, various techniques are applied to stimulate these points and ensure the continuation of the energy flow.In this study, the seed massage technique, which does not cause any side effects among the hand massage stimulation methods, requires a basic level certificate for its use, does not require being a health professional, and can be easily applied by anyone, will be used. Seed massage is a method applied by first detecting pain through a probe on the points of the organs reflected on the hand |
|
Kein Eingriff: standard maintenance
group not receiving seed therapy ( su- jok) |
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Visual Analog Scale (VAS)
Zeitfenster: At baseline (pre-intervention) and immediately after completion of seed therapy]
|
Description: VAS is a scale created in the range of 0-10 cm. According to the scale, 0 cm means the pain is not severe at all, and 10 cm means unbearable pain. On the scale, 0-44 mm indicates mild pain, 45-74 mm indicates moderate pain, and 75-100 mm indicates severe pain. Time Frame: At baseline (pre-intervention) and immediately after completion of seed therapy. |
At baseline (pre-intervention) and immediately after completion of seed therapy]
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Daily Menstrual Symptom Assessment Scale (DMSA)
Zeitfenster: At baseline (pre-intervention) and immediately after completion of seed therapy]
|
The GMMSS was developed by Taylor in 1979 to assess symptoms and their severity during menstruation. The Turkish validity and reliability of the scale were established by Oskay et al. in 2008. The scale consists of seventeen items, with each symptom severity scored between 0 and 5, and there are no subscales. An increase in the score indicates an increase in symptom severity. In Oskay et al.'s study, the Cronbach's alpha value of the scale was found to be 0.88. [Time Frame: Initially (before intervention) and immediately after completion of insemination treatment] |
At baseline (pre-intervention) and immediately after completion of seed therapy]
|
Mitarbeiter und Ermittler
Sponsor
Ermittler
- Hauptermittler: Esra GÜNEY, PhD, Inonu University
Publikationen und hilfreiche Links
Nützliche Links
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- 7879
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Beschreibung des IPD-Plans
Research results will be shared
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Produkt, das in den USA hergestellt und aus den USA exportiert wird
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .